1. Home
  2. SNGX vs ICCT Comparison

SNGX vs ICCT Comparison

Compare SNGX & ICCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNGX
  • ICCT
  • Stock Information
  • Founded
  • SNGX 1987
  • ICCT 1992
  • Country
  • SNGX United States
  • ICCT United States
  • Employees
  • SNGX N/A
  • ICCT N/A
  • Industry
  • SNGX Biotechnology: Pharmaceutical Preparations
  • ICCT Computer Software: Prepackaged Software
  • Sector
  • SNGX Health Care
  • ICCT Technology
  • Exchange
  • SNGX Nasdaq
  • ICCT Nasdaq
  • Market Cap
  • SNGX 6.5M
  • ICCT 6.7M
  • IPO Year
  • SNGX 1987
  • ICCT N/A
  • Fundamental
  • Price
  • SNGX $2.17
  • ICCT $2.60
  • Analyst Decision
  • SNGX
  • ICCT
  • Analyst Count
  • SNGX 0
  • ICCT 0
  • Target Price
  • SNGX N/A
  • ICCT N/A
  • AVG Volume (30 Days)
  • SNGX 198.8K
  • ICCT 49.6M
  • Earning Date
  • SNGX 05-09-2025
  • ICCT 05-14-2025
  • Dividend Yield
  • SNGX N/A
  • ICCT N/A
  • EPS Growth
  • SNGX N/A
  • ICCT N/A
  • EPS
  • SNGX N/A
  • ICCT N/A
  • Revenue
  • SNGX $119,371.00
  • ICCT $11,049,477.00
  • Revenue This Year
  • SNGX N/A
  • ICCT N/A
  • Revenue Next Year
  • SNGX N/A
  • ICCT N/A
  • P/E Ratio
  • SNGX N/A
  • ICCT N/A
  • Revenue Growth
  • SNGX N/A
  • ICCT 42.66
  • 52 Week Low
  • SNGX $1.68
  • ICCT $0.24
  • 52 Week High
  • SNGX $14.83
  • ICCT $27.80
  • Technical
  • Relative Strength Index (RSI)
  • SNGX 52.69
  • ICCT 49.97
  • Support Level
  • SNGX $1.97
  • ICCT $1.84
  • Resistance Level
  • SNGX $2.21
  • ICCT $3.57
  • Average True Range (ATR)
  • SNGX 0.15
  • ICCT 1.24
  • MACD
  • SNGX 0.03
  • ICCT -0.17
  • Stochastic Oscillator
  • SNGX 86.96
  • ICCT 11.95

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

About ICCT iCoreConnect Inc. Common stock

iCoreConnect Inc develops and markets secure cloud-based HIPAA compliant software services focused on compliance, workflow/productivity, and electronic health records systems. Its core services technology can be adopted to other vertical markets that require a high degree of secure data communication, such as the legal, financial, and education fields. It markets secure HIPAA compliant cloud-based software as a service (SaaS) offering under the names of iCoreExchange, iCoreCodeGenius, iCoreSecure, iCoreMD, iCoreDental, iCoreMobile, iCoreHuddle, iCoreRx, iCorePDMP, iCoreEPCS, and iCorePay. The company's software is sold under annual recurring revenue subscriptions. The company has a single reporting segment for reporting purposes focused on the North American market.

Share on Social Networks: